RECEIVED CENTRAL FAX CENTER

SEP 05 2006

USSN: 09/719,410 0206-UTL-9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GOKE, et al

Art Unit:

1654

Appln. No.: 09/719,410

Examiner:

Mohamed, A.

Filed:

12-Dec-2000

Atty. Docket:

0206-UTL-9

For:

GLUCAGON-LIKE PEPTIDE-1 IMPROVES BETA-CELL RESPONSE TO GLUCOSE IN

SUBJECTS WITH IMPARIED GLUCOSE

TOLERANCE (AMENDED)

Confirm. No.: 8826

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

FACSIMILE TRANSMITTAL COVER SHEET

Certificate of Transmission Under 37 C.F.R. 1.8

The following documents are being submitted via facsimile transmittal in response to the Non-Final Office Action Due, mailed June 5, 2006:

Documents(s)		No. of Pages
Response Under 37 C.F.R. 1.111		6
Facsimile Cover Sheet		1
	Total Pages	7

Should any other fee become due or credit become payable during the pendency of these proceedings, the Commissioner is authorized to charge or credit the same to Deposit Account Number 010535.

I hereby certify that the following listed correspondence in the above-referenced application is being transmitted by facsimile to the Commissioner for Patents, Alexandria, VA to telephone number to telephone number (571) 273-8300 on this 5th day of September, 2006.

RECEIVED CENTRAL FAX CENTER

SEP 0 5 2006

USSN 09/719,410 Atty Docket No. 0206-UTL-9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GOKE, et al

Art Unit:

1654

Appln. No.: 09/719,410

Examiner:

Mohamed, A.

Filed:

12-Dec-2000

Atty. Docket:

0206-UTL-9

For:

GLUCAGON-LIKE PEPTIDE-1 IMPROVES

BETA-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPARIED GLUCOSE

TOLERANCE (AMENDED)

Confirm. No.: 8826

RESPONSE UNDER 37 C.F.R. 1.111

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Sir:

In response to the Office action dated June 5, 2006, Applicant respectfully submits the following amendments and remarks in connection with the above-identified application.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this response.

Remarks begin on page 5 of this response.